Stay tuned

NEWS

SwissMedic – the Swiss Federal Agency for Therapeutic Products – granted SpinoSave® the swiss orphan status designation for the treatment of acute spinal cord injury.

17/07/2024

EMA orphan medicinal product designation for SpinoSave®

18/04/2024

The European Medicines Agency’s Committee for Advanced Therapies has classified SpinoSave® as an Advanced Therapy Medicinal Product (ATMP), with the subclassification of Tissue Engineered Product (TEP).

16/02/2023
Our treatment classification has been issued under nr. EMA/CAT/12870/2023.

Regenera GmbH is awarded the European Seal of Excellence within the EU Horizon Accelerator Program.

14/12/2022

Regenera GmbH successfully closes its first seed investment round with the Austrian investment fund ILUMTec GmbH.

04/11/2022

Regenera SA is incubated at the University of Southern Switzerland (USI) Startup Centre.

28/09/2022

Regenera GmbH becomes member of the Austrian Cluster for Tissue Regeneration.

26/08/2022

Regenera SA, Lugano Switzerland, becomes a fully owned subsidiary of Regenera GmbH.

29/07/2022

Regenera GmbH is incorporated in Vienna, Austria, under the Austrian Federal Law.

27/07/2022

Regenera SA cooperates with the neuroregeneration lab of the University of Southern Switzerland (USI) as partner of the InnoSuisse Grant nr. 59351.1 IP-LS.

02/05/2022

Regenera SA is incorporated in Lugano, Switzerland, under the Swiss Federal Law.

21/07/2021